{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.8","upperLimit":"6.6","value":"5.7"},{"groupId":"OG001","lowerLimit":"1.8","upperLimit":"2.8","value":"2.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"385"},{"groupId":"OG001","value":"196"}],"units":"Participants"}],"description":"Time to worsening was defined as the time from randomization to the first occurring of a \\>=10 point decrease in FACT-P total score compared to baseline, clinical disease progression, or death.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients randomized to receive the investigational product received 7.4 GBq (+/- 10%) 177Lu-PSMA-617 intravenously every 6 weeks (+/- 1 week) for a maximum of 6 cycles. Best supportive/best standard of care (BS/BSOC) might be used","id":"OG000","title":"Main Study: 177Lu-PSMA-617 Plus Best Supportive/Best Standard of Care (BS/BSOC)"},{"description":"Patients randomized to this arm received best supportive/best standard of care (BS/BSOC) as determined by the investigator","id":"OG001","title":"Main Study: Best Supportive/Best Standard of Care (BS/BSOC) Alone"}],"paramType":"MEDIAN","populationDescription":"PFS-Full analysis set","reportingStatus":"POSTED","timeFrame":"From date of randomization until date of End of Treatment (EoT), assessed up to 32 months (Primary Analysis cut-off date = 27-Jan-2021)","title":"Time to Worsening in FACT-P Total Score","type":"SECONDARY","unitOfMeasure":"Months"}